Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 8Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Endometrioid 1Brain Neoplasms 1

Interventions

vistusertib 2toripalimab 1tislelizumab 1tanespimycin 1sargramostim 1roniciclib 1abemaciclib 1Letrozole 1Ipilimumab 1Hydroxychloroquine 1Fulvestrant 1Anastrozole 1Albumin-Bound Paclitaxel 1AMG 337 14-toluenesulfonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Solid Tumor × Fulvestrant × Clear all
NCT04316169 2022-12-23

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Medical College of Wisconsin

Phase 1 Withdrawn
BreastOther solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡